Clinical trial NCT06065540: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Official title: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2023-10-04
Enrollment: 2734
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).


Eligibility criteria: Inclusion Criteria:

* Male or female (sex at birth).
* Age 18 years or above at the time of signing the informed consent.
* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening.
* Stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors.
* Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening.
* Body Mass Index (BMI) greater than or equal to 25 kilogram per square metre ( kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Exclusion Criteria:

* Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square metre (mL/min/1.73 m\^2) as determined by central laboratory at screening.
* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.

Primary outcomes:
measure: CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)
timeFrame: From baseline (week 0) to end of treatment (week 68)
Secondary outcomes:
measure: CagriSema versus cagrilintide: Change in HbA1c
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus cagrilintide: Relative change in body weight
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema (dose 1) versus semaglutide (dose 2): Change in HbA1c
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Relative change in body weight
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Cagrilintide versus placebo: Change in HbA1c
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: Cagrilintide versus placebo: Relative change in body weight
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Achievement of greater than or equal to (>=) 10 percent (%) weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Achievement of >= 15 % weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Achievement of >= 20 % weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema (pooled doses) versus semaglutide (pooled doses): Continuous Glucose Monitoring (CGM) - Change in Time in Range (TIR) 3.9-10.0 millimoles per litre (mmol/L) (70-180 milligrams per decilitre [mg/dL])
timeFrame: From baseline (week -3) to end of treatment (week 68)
measure: CagriSema versus semaglutide: CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 (mmol/L) (70-140 mg/dL)
timeFrame: From baseline (week -3) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in Systolic Blood Pressure (SBP)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in triglycerides
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
timeFrame: From baseline (week -3) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in Fasting Plasma Glucose (FPG)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
timeFrame: At end of treatment (week 68)
measure: CagriSema versus semaglutide: Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol)
timeFrame: At end of treatment (week 68)
measure: CagriSema versus semaglutide: CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: CGM - Within-day glycaemic variability (% coefficient of variation [CV])
timeFrame: At end of treatment (week 68)
measure: CagriSema versus semaglutide: Achievement of ≥ 5 % weight reduction
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in waist circumference
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in Diastolic Blood Pressure (DBP)
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in total cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in HDL cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in low-density lipoprotein (LDL) cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Ratio to baseline in free fatty acids
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in Short Form (SF)-36v score- Physical component summary score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in SF-36v2 score- Mental component summary score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide: Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score
timeFrame: From baseline (week 0) to end of treatment (week 68)
measure: CagriSema versus semaglutide, placebo and cagrilintide: Number of treatment emergent adverse events (TEAEs)
timeFrame: From baseline (week 0) to end of study (week 75)
measure: CagriSema versus semaglutide: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)
timeFrame: From baseline (week 0) to end of study (week 75)
measure: CagriSema versus semaglutide: Number of severe hypoglycaemic episodes (level 3)
timeFrame: From baseline (week 0) to end of study (week 75)
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Univ of Alabama_Birmingham
state: Alabama
city: Pelham
country: United States
facility: Cahaba Research
state: Alabama
city: Phoenix
country: United States
facility: Velocity Clinical Research-Phoenix
state: Arizona
city: Phoenix
country: United States
facility: Synexus Rsch /Cnt Phnx Med C
state: Arizona
city: Little Rock
country: United States
facility: Arkansas Clinical Research
state: Arkansas
city: Banning
country: United States
facility: Velocity Clinical Res-Banning
state: California
city: Chula Vista
country: United States
facility: Velocity Clin Res-Chula Vista
state: California
city: Concord
country: United States
facility: John Muir Physicians Network
state: California
city: Escondido
country: United States
facility: Headlands Research California, LLC
state: California
city: Gardena
country: United States
facility: Velocity Clin Res Gardena
state: California
city: La Mesa
country: United States
facility: Velocity Clin Res San Diego
state: California
city: Loma Linda
country: United States
facility: Loma Linda Univ Hlth Cr Endo
state: California
city: Mission Hills
country: United States
facility: Facey Medical Foundation
state: California
city: Palm Springs
country: United States
facility: Desert Oasis Hlthcr Med Group
state: California
city: Palm Springs
country: United States
facility: Desert Oasis Hlthcr Med Group
state: California
city: San Bernardino
country: United States
facility: Velocity Clin Res- San Bern
state: California
city: San Diego
country: United States
facility: Linda Vista Health Care Ctr
state: California
city: Santa Ana
country: United States
facility: Velocity Clin Res Santa Ana
state: California
city: Toluca Lake
country: United States
facility: Premier Medical Center, Inc.
state: California
city: Van Nuys
country: United States
facility: Velocity Clin Res - Panorama
state: California
city: Colorado Springs
country: United States
facility: Optumcare Colorado Springs
state: Colorado
city: Jacksonville
country: United States
facility: Northeast Research Institute
state: Florida
city: Miami
country: United States
facility: Clinical Trial Services Corp
state: Florida
city: Miami
country: United States
facility: Bioclinical Research Alliance
state: Florida
city: Miami
country: United States
facility: New Horizon Research Center
state: Florida
city: Miramar
country: United States
facility: South Broward Research LLC
state: Florida
city: Ocoee
country: United States
facility: West Orange Endocrinology
state: Florida
city: Orange City
country: United States
facility: Optimal Research Sites
state: Florida
city: Orlando
country: United States
facility: AdventHealth Diab Inst
state: Florida
city: Conyers
country: United States
facility: Hope Clin Res & Wellness
state: Georgia
city: Macon
country: United States
facility: East Coast Institute for Res
state: Georgia
city: Roswell
country: United States
facility: Endocrine Research Solutions, Inc.
state: Georgia
city: Roswell
country: United States
facility: Endocrine Research Solutions
state: Georgia
city: Boise
country: United States
facility: St. Luke's Health System
state: Idaho
city: Meridian
country: United States
facility: Solaris Clinical Research
state: Idaho
city: Chicago
country: United States
facility: Cedar-Crosse Research Center
state: Illinois
city: Gurnee
country: United States
facility: Clinical Invest Special_Gurnee
state: Illinois
city: Skokie
country: United States
facility: Endeavor Health
state: Illinois
city: Skokie
country: United States
facility: Evanston Premier Hlthcr Res
state: Illinois
city: West Des Moines
country: United States
facility: Iowa Diabetes & Endo Res Ctr
state: Iowa
city: Newton
country: United States
facility: Alliance for Multispec Res
state: Kansas
city: Topeka
country: United States
facility: Cotton-O'Neil Diab & Endo Ctr
state: Kansas
city: Lafayette
country: United States
facility: Velocity Clin Res Lafayette
state: Louisiana
city: New Bedford
country: United States
facility: BTC of New Bedford, LLC
state: Massachusetts
city: Gulfport
country: United States
facility: Velocity Clin Res Gulfport
state: Mississippi
city: Chesterfield
country: United States
facility: Diabetes & Endo Specialists Inc
state: Missouri
city: Trenton
country: United States
facility: Premier Research Inc.
state: New Jersey
city: Albuquerque
country: United States
facility: Velocity Clin Res Albuquerque
state: New Mexico
city: Albany
country: United States
facility: Albany Medical College - Endo
state: New York
city: East Syracuse
country: United States
facility: Velocity Clin Res Syracuse
state: New York
city: West Seneca
country: United States
facility: Southgate Medical Group, LLP
state: New York
city: Westfield
country: United States
facility: Great Lakes Medical Research
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina
state: North Carolina
city: Greensboro
country: United States
facility: PharmQuest Life Sciences LLC
state: North Carolina
city: Morehead City
country: United States
facility: Carteret Medical Group
state: North Carolina
city: Statesville
country: United States
facility: Piedmont Healthcare/Research
state: North Carolina
city: Wilmington
country: United States
facility: Accellacare
state: North Carolina
city: Akron
country: United States
facility: Radiant Research Inc. - Akron
state: Ohio
city: Dublin
country: United States
facility: Aventiv Research
state: Ohio
city: Norman
country: United States
facility: Alliance for Multispec Res
state: Oklahoma
city: Cumberland
country: United States
facility: Clinical Res Collaborative
state: Rhode Island
city: East Greenwich
country: United States
facility: Velocity Clin Res Providence
state: Rhode Island
city: Anderson
country: United States
facility: AnMed Health IMA
state: South Carolina
city: Anderson
country: United States
facility: Synexus Clin Res US-Anderson
state: South Carolina
city: Anderson
country: United States
facility: Velocity Clinical Res-Anderson
state: South Carolina
city: Gaffney
country: United States
facility: Velocity Clin Res Gaffney
state: South Carolina
city: Spartanburg
country: United States
facility: Spartanburg Medical Research
state: South Carolina
city: Spartanburg
country: United States
facility: Velocity Clin Res Spartanburg
state: South Carolina
city: Bristol
country: United States
facility: Holston Medical Group Pc
state: Tennessee
city: Kingsport
country: United States
facility: Holston Medical Group
state: Tennessee
city: Nashville
country: United States
facility: Clinical Research Associates
state: Tennessee
city: Arlington
country: United States
facility: Arlington Family Res. Ctr Inc
state: Texas
city: Austin
country: United States
facility: Velocity Clin Res Austin
state: Texas
city: Dallas
country: United States
facility: Velocity Clinical Res-Dallas
state: Texas
city: Dallas
country: United States
facility: North Texas Endocrine Center
state: Texas
city: Dallas
country: United States
facility: Synexus Clin Res Dallas
state: Texas
city: Dallas
country: United States
facility: Cedar Health Research
state: Texas
city: Houston
country: United States
facility: Juno Research, LLC_Houston
state: Texas
city: Houston
country: United States
facility: Synergy Groups Medical
state: Texas
city: Houston
country: United States
facility: PlanIt Research, PLLC
state: Texas
city: Katy
country: United States
facility: Medical Colleagues-Texas LLP
state: Texas
city: Kerrville
country: United States
facility: Sante Clinical Research
state: Texas
city: Missouri City
country: United States
facility: Discovery MMS Services, INC
state: Texas
city: San Antonio
country: United States
facility: AES San Antonio
state: Texas
city: San Antonio
country: United States
facility: University of Texas San Antonio
state: Texas
city: San Antonio
country: United States
facility: NE Clin Res of San Antonio
state: Texas
city: Shavano Park
country: United States
facility: Consano Clinical Research, LLC
state: Texas
city: Tomball
country: United States
facility: DM Clin Rsrch/Fam Diag Clinic
state: Texas
city: Sandy
country: United States
facility: Diabetes & Endo Treatment Spec
state: Utah
city: West Jordan
country: United States
facility: Velocity Clin Res-Salt Lk City
state: Utah
city: Newport News
country: United States
facility: TPMG Clinical Research
state: Virginia
city: Renton
country: United States
facility: Rainier Clin Res Ctr Inc
state: Washington
city: Green Bay
country: United States
facility: St. Vincent Hosp-Prevea Health
state: Wisconsin
city: Caba
country: Argentina
facility: Mautalen Salud e investigación
state: Buenos Aires
city: Caba
country: Argentina
facility: Sanatorio Güemes
state: City Of Buenos Aires
city: Rosario
country: Argentina
facility: Instituto de Investigaciones Clínicas Rosario
state: Santa Fe
city: Buenos Aires
country: Argentina
facility: STAT Research
city: Buenos Aires
country: Argentina
facility: Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
city: Caba
country: Argentina
facility: Centro de Investigación y Prevención Cardiovascular
city: Camperdown
country: Australia
facility: Clinical Research Facility, Charles Perkins Centre
state: New South Wales
city: Darlinghurst
country: Australia
facility: Momentum Clinical Research Darlinghurst
state: New South Wales
city: Macquarie Park
country: Australia
facility: Macquarie University
state: New South Wales
city: Merewether
country: Australia
facility: Hunter Diabetes Centre
state: New South Wales
city: Meadowbrook
country: Australia
facility: Logan Hospital
state: Queensland
city: Oaklands Park
country: Australia
facility: Southern Adelaide Diabetes & Endocrine Services
state: South Australia
city: Fitzroy
country: Australia
facility: St Vincent's Hospital - Melbourne
state: Victoria
city: Melbourne
country: Australia
facility: Baker Heart and Diabetes Institute
state: Victoria
city: Curitiba
country: Brazil
facility: Cline Research Center
state: Parana
city: São Paulo
country: Brazil
facility: CPQuali Pesquisa Clínica Ltda
state: Sao Paulo
city: São Paulo
country: Brazil
facility: CPCLIN - Centro de Pesquisas Clínicas
state: Sao Paulo
city: Burgas
country: Bulgaria
facility: "IPSMC - d-r Nikolay Kostadinov" EOOD
city: Gotse Delchev
country: Bulgaria
facility: "Dr Tatyana Metalova - ambulatory for individual practice for specialised medical care for endocrinology" EOOD
city: Lom
country: Bulgaria
facility: Medical Center Zdrave Lom
city: Razgrad
country: Bulgaria
facility: Medical centre Razgrad OOD
city: Sofia
country: Bulgaria
facility: Diagnostic Consulting Center Ascendent
city: Sofia
country: Bulgaria
facility: "Medical Center Maraya Med" EOOD
city: Varna
country: Bulgaria
facility: Medical centre Clinic Nova
city: Varna
country: Bulgaria
facility: UMHAT Sveta Marina EAD
city: Calgary
country: Canada
facility: Centricity Research Calgary
state: Alberta
city: Surrey
country: Canada
facility: Guilford Med Clinic
state: British Columbia
city: Surrey
country: Canada
facility: TLC Diabetes and Endocrinology
state: British Columbia
city: Surrey
country: Canada
facility: Ocean West Research Clinic
state: British Columbia
city: Surrey
country: Canada
facility: Hilltop Medical Clinic
state: British Columbia
city: Vancouver
country: Canada
facility: Spectrum Health Clinic
state: British Columbia
city: Moncton
country: Canada
facility: G.A. Research Associates Ltd.
state: New Brunswick
city: Barrie
country: Canada
facility: Centricity Res. Barrie Endo
state: Ontario
city: Brampton
country: Canada
facility: Centricity Research Brampton
state: Ontario
city: Concord
country: Canada
facility: Centricity Research Vaughn
state: Ontario
city: Courtice
country: Canada
facility: Medical Trust Clinics, Inc.
state: Ontario
city: Etobicoke
country: Canada
facility: Centricity Research Etobicoke
state: Ontario
city: London
country: Canada
facility: Milestone Research
state: Ontario
city: London
country: Canada
facility: Western Univ. Cnt for Studies in Fam Med
state: Ontario
city: Nepean
country: Canada
facility: Centricity Research Ottawa LMC
state: Ontario
city: Toronto
country: Canada
facility: Centricity Research Toronto
state: Ontario
city: Toronto
country: Canada
facility: Diabetes Heart Research Centre
state: Ontario
city: Montreal
country: Canada
facility: Centre Medical Acadie
state: Quebec
city: Pointe-Claire
country: Canada
facility: Centricity Res Pointe-Claire
state: Quebec
city: Quebec City
country: Canada
facility: ALPHA Recherche Clinique
state: Quebec
city: Terrebonne
country: Canada
facility: Ctr de Med Metab de Lanaudiere
state: Quebec
city: Victoriaville
country: Canada
facility: Diex Recherche Victoriaville
state: Quebec
city: Quebec
country: Canada
facility: Diex Recherche Quebec Inc.
city: Quebec
country: Canada
facility: Clin des Mal Lipid de Quebec
city: Quebec
country: Canada
facility: Centre de Recherche Saint-Louis
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University-Endocrinology
state: Beijing
city: Beijing
country: China
facility: Chinese People's Liberation Army General Hospital-Endocrinology
state: Beijing
city: Chongqing
country: China
facility: Chongqing University Three Gorges Hospital
state: Chongqing
city: Kaifeng
country: China
facility: Huaihe Hospital of Henan University-Endocrinology
state: Henan
city: Nanjing
country: China
facility: The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
state: Jiangsu
city: Suzhou
country: China
facility: Suzhou Municipal Hospital-Endocrinology
state: Jiangsu
city: Zhenjiang
country: China
facility: The Affiliated Hospital of Jiangsu University-Endocrinology
state: Jiangsu
city: Ji'Nan
country: China
facility: Jinan Central Hospital
state: Shandong
city: Zagreb
country: Croatia
facility: Poliklinika Solmed
state: Grad Zagreb
city: Osijek
country: Croatia
facility: Poliklinika SLAVONIJA OSIJEK
state: Osječko - Baranjska Županija
city: Rijeka
country: Croatia
facility: KBC Rijeka, Endokrinologija
state: Primorsko - Goranska Županija
city: Opatija
country: Croatia
facility: Thalassotherapia Opatija
city: Slavonski Brod
country: Croatia
facility: Opca bolnica Dr. Josip Bencevic
city: Varazdin
country: Croatia
facility: Opca bolnica Varazdin
city: Praha 4
country: Czechia
facility: IKEM Centrum Diabetologie
state: Czech Republic
city: Brno
country: Czechia
facility: University Hospital U sv. Anny
city: Broumov
country: Czechia
facility: Edumed Broumov
city: Holešov
country: Czechia
facility: Diahaza s.r.o.
city: Plzeň 3
country: Czechia
facility: DIALINE s.r.o.
city: Praha 1
country: Czechia
facility: Diabet2 s.r.o.
city: Praha 4
country: Czechia
facility: MUDr. Michala Pelikanova
city: Aarhus N
country: Denmark
facility: Aarhus Universitetshospital, Steno Diabetes Center Aarhus
city: Herlev
country: Denmark
facility: Steno Diabetes Center Copenhagen
city: Hillerød
country: Denmark
facility: Hillerød Endokrinologisk amb. H0652
city: Hvidovre
country: Denmark
facility: Hvidovre Hospital Endokrinologisk forsk. afs. 159
city: København
country: Denmark
facility: Bispebjerg Hospital, IC-Forskning
city: Odense C
country: Denmark
facility: Steno Diabetes Center Odense
city: Jyväskylä
country: Finland
facility: Terveystalo Jyväskylä
city: Seinäjoki
country: Finland
facility: Seinäjoen keskussairaala
city: Tampere
country: Finland
facility: Pihlajalinna Koskiklinikka
city: Tampere
country: Finland
facility: Terveystalo Tampere Rautatienkatu
city: Turku
country: Finland
facility: Turku University Hospital
city: Berlin
country: Germany
facility: Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
city: Daaden
country: Germany
facility: Diabetologische Schwerpunktpraxis Daaden
city: Dortmund
country: Germany
facility: Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
city: Dresden
country: Germany
facility: Uniklinik TU Dresden Med. Klinik III
city: Elsterwerda
country: Germany
facility: Zentrum fuer klinische Studien Suedbrandenburg GmbH
city: Essen
country: Germany
facility: InnoDiab Forschung GmbH
city: Gelnhausen
country: Germany
facility: MVZ Diabeteszentrum Dr. Tews GmbH
city: Hamburg
country: Germany
facility: Diabetes-Zentrum-Wilhelmsburg GbR
city: Hamburg
country: Germany
facility: Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR
city: Lingen
country: Germany
facility: Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
city: Ludwigshafen
country: Germany
facility: Die Praxis am Ludwigsplatz
city: Lübeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck
city: München
country: Germany
facility: Medicover Neuroendokrinologie MVZ
city: Oldenburg in Holstein
country: Germany
facility: RED-Institut für medizinische Forschung und Fortbildung GmbH
city: Athens
country: Greece
facility: University Hospital of Athens ATTIKON
state: Attica
city: Nea Efkarpia
country: Greece
facility: General Hospital Of Thessaloniki Papageorgiou
state: Thessaloniki
city: Athens
country: Greece
facility: Iatriko Psychicou Private Clinic
city: Athens
country: Greece
facility: "Laiko" General Hospital of Athens
city: Athens
country: Greece
facility: General hospital of Athens 'G.Gennimatas'
city: Athens
country: Greece
facility: Iatriko Athinon (Athens Medical Canter)
city: Larissa
country: Greece
facility: Univ Gen Hospital Larisa
city: Thessaloniki
country: Greece
facility: "AHEPA" University Hospital of Thessaloniki
city: Thessaloniki
country: Greece
facility: "AHEPA" University Hospital of Thessaloniki
city: Thessaloniki
country: Greece
facility: "Ippokrateio" G.H. of Thessaloniki
city: Thessaloniki
country: Greece
facility: EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
city: Szeged
country: Hungary
facility: Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
state: Csongrád-Csanád
city: Debrecen
country: Hungary
facility: Debreceni Egyetem Belgyógyászati Klinika
state: Hajdu-Bihar
city: Budapest
country: Hungary
facility: Óbudai Egészségügyi Centrum
city: Budapest
country: Hungary
facility: Bajcsy-Zsilinszky Kórház
city: Budapest
country: Hungary
facility: MH Egészségügyi Központ
city: Kaposvár
country: Hungary
facility: Kaposi Mór Oktató Kórház
city: Szombathely
country: Hungary
facility: Markusovszky Egyetemi Oktatókórház
city: Vijaywada
country: India
facility: Yalamanchi Hospitals and Research centres pvt ltd
state: Andhra Pradesh
city: Guwahati
country: India
facility: Gauhati Medical College and Hospital
state: Assam
city: Bengaluru
country: India
facility: Lifecare Hospital and Research Centre
state: Karnataka
city: Mysuru
country: India
facility: K R Hospital
state: Karnataka
city: Thane
country: India
facility: Ashirwad Hospital and Research Centre
state: Maharashtra
city: Jaipur
country: India
facility: SMS Medical College & Hospital
state: Rajasthan
city: Chennai
country: India
facility: Madras Diabetes Research Foundation
state: Tamil Nadu
city: Hyderabad
country: India
facility: Gleneagles Hospitals
state: Telangana
city: Hyderabad
country: India
facility: Dr P V Rao - Diabetes Research Centre
state: Telangana
city: Kolkata
country: India
facility: Apollo Multispeciality Hospital, Kolkata
state: West Bengal
city: Ahmedabad
country: India
facility: Swasthya Diabetes Care
city: New Delhi
country: India
facility: Lady Hardinge Medical College
city: Haifa
country: Israel
facility: Linn clinic - Clalit Health Services
city: Herzeliya
country: Israel
facility: Clalit sick fund Herzeliya
city: Herzlia
country: Israel
facility: Clalit sick fund Herzlia
city: Holon
country: Israel
facility: Diabetes Clinic Wolfson MC
city: Jerusalem
country: Israel
facility: Diabetes Unit Hadassah Ein Karem MC
city: Rehovot
country: Israel
facility: Kaplan MC
city: Tel Hashomer
country: Israel
facility: Endrocrinolgy Clinic - Sheba Medical Center
city: Firenze
country: Italy
facility: AOU Careggi Firenze
state: Fi
city: Milano
country: Italy
facility: Istituto Scientifico San Raffaele
state: MI
city: Firenze
country: Italy
facility: AOU Careggi Firenze
state: Toscana
city: Arezzo
country: Italy
facility: Azienda Sanitaria Usl Toscana Sud Est - Ospedale San Donato
city: Bergamo
country: Italy
facility: Azienda Ospedaliera Papa Giovanni XXIII
city: Catanzaro
country: Italy
facility: Azienda Ospedaliero-Universitaria Renato Dulbecco
city: Chieti Scalo
country: Italy
facility: Università degli studi G. D'Annunzio Chieti Pescara - CAST
city: Milano
country: Italy
facility: Azienda Ospedaliera Luigi Sacco
city: Napoli
country: Italy
facility: Azienda Ospedaliera Universitaria Federico II di Napoli
city: Palermo
country: Italy
facility: AOUP Giaccone Palermo
city: Palermo
country: Italy
facility: Dip. di Medicina Interna Policlinico Universitario Palermo
city: Roma
country: Italy
facility: Azienda Ospealiero Universitaria Policlinico Umberto I
city: Rome
country: Italy
facility: Policlinico A. Gemelli
city: Koriyama-shi
country: Japan
facility: Seino Internal Medicine Clinic
state: Fukushima, Japan
city: Oita-shi
country: Japan
facility: Abe Diabetes Clinic_Internal Medicine
state: Oita, Japan
city: Chiba-shi, Chiba
country: Japan
facility: Akaicho Clinic
city: Ibaraki
country: Japan
facility: Naka Kinen Clinic
city: Mito-shi, Ibaraki
country: Japan
facility: Minami Akatsuka Clinic
city: Osaka-shi, Osaka
country: Japan
facility: Medical Research Institute KITANO HOSPITAL, Diabetes & Endocrinology
city: Tokyo
country: Japan
facility: Tokyo-Eki Center-building Clinic
city: Tokyo
country: Japan
facility: Fukuwa Clinic
city: Bucheon-si
country: Korea, Republic of
facility: The catholic university of Korea, Bucheon St.Mary's Hospital
state: Gyeonggi-do
city: Daegu
country: Korea, Republic of
facility: Yeungnam University Medical Center
city: Gwangju
country: Korea, Republic of
facility: Chosun University Hospital
city: Seoul
country: Korea, Republic of
facility: Kyunghee University Medical Center
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Mexicali
country: Mexico
facility: Centro de investigación en Artritis y Osteoporosis S.C.
state: Baja California
city: Guadalajara
country: Mexico
facility: Centro de Investigacion Clinica Endocrinologica de Jalisco
state: Jalisco
city: Lodz
country: Poland
facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika
state: Lodzkie
city: Gorzow Wielkopolski
country: Poland
facility: Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
state: Lubuskie
city: Chrzanow
country: Poland
facility: Malopolskie Centrum Sercowo-Naczyniowe
state: Malopolskie
city: Warszawa
country: Poland
facility: Instytut Diabetologii Sp. z o.o.
state: Mazovian Voivodeship
city: Rzeszow
country: Poland
facility: Centrum Medyczne Medyk Sp. z o.o.
state: Podkarpackie
city: Bialystok
country: Poland
facility: Osteo Medic s.c. Artur Racewicz Jerzy Supronik
state: Podlaskie
city: Bialystok
country: Poland
facility: NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
state: Podlaskie
city: Dąbrowa-Górnicza
country: Poland
facility: PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
state: Slaskie
city: Tychy
country: Poland
facility: PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
state: Slaskie
city: Lublin
country: Poland
facility: Velocity Nova Sp. z o.o.
city: Pulawy
country: Poland
facility: KO-MED Centra Kliniczne Sp. z o.o.
city: Staszow
country: Poland
facility: Velocity Nova Sp. z o.o.
city: Warszawa
country: Poland
facility: NBR Polska Tomasz Klodawski
city: Warszawa
country: Poland
facility: Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
city: Staszow
country: Poland
facility: Velocity Nova Sp. z o.o.
state: Świętokrzyskie
city: Bucharest
country: Romania
facility: Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
state: Bucurestii
city: Cluj Napoca
country: Romania
facility: Spitalul Clinic Judetean Urgenta Cluj-Napoca
state: Cluj
city: Ploiesti
country: Romania
facility: Diabmed Dr Popescu Alexandrina SRL
state: Prahova
city: Ploiesti
country: Romania
facility: CMI Dr. Busegeanu Mihaela Magdalena
state: Prahova
city: Zalau
country: Romania
facility: Cabinet Medical de Diabet, Nutritie si Boli Metabolice-Dr. Zaharie Daniela Gabriela
state: Salaj
city: Bacau
country: Romania
facility: CMI Dr. Pletea Noemi SRL
city: Brasov
country: Romania
facility: Mariodiab Clinic SRL
city: Brasov
country: Romania
facility: Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed
city: Bucuresti
country: Romania
facility: Diabet Med SRL
city: Craiova
country: Romania
facility: Urodiamed SRL
city: Galati
country: Romania
facility: S.C Milena Sante SRL
city: Pascani
country: Romania
facility: Bella Praxis S.R.L.
city: Reghin
country: Romania
facility: Poli Cardinal Med Srl
city: Novi Sad
country: Serbia
facility: Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
state: Vojvodina
city: Belgrade
country: Serbia
facility: CHC Zvezdara, Clinical department for endocrinology
city: Belgrade
country: Serbia
facility: Endocrinology, Diabetes and Metabolism Diseases Clinic
city: Belgrade
country: Serbia
facility: Clinical Hospital Center Bezanijska Kosa
city: Kragujevac
country: Serbia
facility: Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
city: Kragujevac
country: Serbia
facility: Clinical Centre Kragujevac, Internal Diseases Clinic, Endocr
city: Bardejov
country: Slovakia
facility: DIADA, s.r.o.
city: Kosice
country: Slovakia
facility: Diabetologicka ambulancia DIOLI s.r.o.
city: Kosice
country: Slovakia
facility: DIOLI s.r.o.
city: Malacky
country: Slovakia
facility: MediVet s.r.o.
city: Presov
country: Slovakia
facility: DIALIPID, s.r.o.
city: Prievidza
country: Slovakia
facility: MUDr. Jan Culak, s.r.o.
city: Ruzomberok
country: Slovakia
facility: DIACENTRUM, s.r.o.
city: Sabinov
country: Slovakia
facility: MEDI-DIA s.r.o.
city: Surany
country: Slovakia
facility: DEImedi, s. r. o.
city: Trebisov
country: Slovakia
facility: ARETEUS s.r.o.
city: Ziar nad Hronom
country: Slovakia
facility: iDia s. r. o.
city: Kocevje
country: Slovenia
facility: Healthcare centre Kocevje
city: Koper
country: Slovenia
facility: Healthcare Centre Koper
city: Ljubljana
country: Slovenia
facility: Dermatologija Bartenjev
city: Maribor
country: Slovenia
facility: UKC Maribor - diabetes
city: Nova Gorica
country: Slovenia
facility: Healtcare Centre Nova Gorica
city: Topolšica
country: Slovenia
facility: Hospital Topolšica
city: Port Elizabeth
country: South Africa
facility: Phoenix Pharma
state: Eastern Cape
city: Johannesburg
country: South Africa
facility: Newtown Clinical Research
state: Gauteng
city: Johannesburg
country: South Africa
facility: Sandton Medical Research
state: Gauteng
city: Kempton Park
country: South Africa
facility: Clinresco Centres (Pty) Ltd
state: Gauteng
city: Pretoria
country: South Africa
facility: Clinical Trial Systems (CTC)
state: Gauteng
city: Paarl
country: South Africa
facility: Paarl Research Centre
state: Western Cape
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
city: La Coruña
country: Spain
facility: Complejo Hospitalario Universitario A Coruña
city: La Roca del Vallés
country: Spain
facility: ABS La Roca del Vallés
city: Móstoles
country: Spain
facility: Hospital Universitario de Móstoles
city: Segovia
country: Spain
facility: Hospital General de Segovia
city: Sevilla
country: Spain
facility: Hospital Infanta Luisa
city: Valencia
country: Spain
facility: Hospital La Fe - Endocrinología y Nutrición
city: Lund
country: Sweden
facility: Clemenstorgets Hjärtmottagning
city: Malmö
country: Sweden
facility: Forskningsmottagning Internmedicin (tidigare KFE)
city: Mölndal
country: Sweden
facility: CTC GoCo Mölndal
city: Stockholm
country: Sweden
facility: Karolinska Universitetssjukhuset Solna,FOU Tema Hjärta Kärl
city: Örebro
country: Sweden
facility: Överviktsenheten Örebro universitetssjukhus
city: Changhua City
country: Taiwan
facility: Changhua Christian Hospital
city: Taipei city
country: Taiwan
facility: Taipei Medical University Hospital
city: Adana
country: Turkey
facility: Cukurova Universitesi Tip Fakultesi
city: Antalya
country: Turkey
facility: Akdeniz University Tip Fakultesi Hastanesi
city: Eskisehir
country: Turkey
facility: Eskisehir Osmangazi University School of Medicine
city: Istanbul
country: Turkey
facility: Haseki Sultangazi
city: Istanbul
country: Turkey
facility: Seyrantepe Hamidiye Etfal Egitim ve Arastirma Hastanesi
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji
city: Istanbul
country: Turkey
facility: Basaksehir Cam ve Sakura Sehir Hastanesi
city: Istanbul
country: Turkey
facility: T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
city: Rize
country: Turkey
facility: Recep Tayyip Erdoğan Üni. Eğitim ve Araştırma Hastanesi
city: Tekirdag
country: Turkey
facility: Tekirdag Namık Kemal UTF
city: Stevenage
country: United Kingdom
facility: Lister Hospital
state: Hertfordshire
city: Pickering
country: United Kingdom
facility: Pickering Medical Practice
state: North Yorkshire
city: Aberdeen
country: United Kingdom
facility: Aberdeen Royal Infirmary
city: Bath
country: United Kingdom
facility: Oldfield Surgery
city: Blackburn
country: United Kingdom
facility: Oakenhurst Surgery
city: Dundee
country: United Kingdom
facility: Ninewells Hospital
city: Liverpool
country: United Kingdom
facility: University Hospital Aintree
city: Norwich
country: United Kingdom
facility: Norfolk and Norwich University Hospital Trust
city: Southampton
country: United Kingdom
facility: Moorgreen Hospital
city: Swansea
country: United Kingdom
facility: Joint Clinical Research Facility - Swansea
city: Truro
country: United Kingdom
facility: Royal Cornwall Hospital (Treliske)
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: